Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A Role for GLP-1 in Treating Hyperphagia and Obesity
Harvey J. Grill
Endocrinology (2020) Vol. 161, Iss. 8
Open Access | Times Cited: 84

Showing 1-25 of 84 citing articles:

Signaling pathways in obesity: mechanisms and therapeutic interventions
Xue Wen, Bohan Zhang, Beiyi Wu, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 231
Central and peripheral GLP-1 systems independently suppress eating
Daniel I. Brierley, Marie K. Holt, Arashdeep Singh, et al.
Nature Metabolism (2021) Vol. 3, Iss. 2, pp. 258-273
Open Access | Times Cited: 170
The role of glucagon‐like peptide 1 (GLP‐1) in addictive disorders
Mette Kruse Klausen, Morgane Thomsen, Gitta Wörtwein, et al.
British Journal of Pharmacology (2021) Vol. 179, Iss. 4, pp. 625-641
Open Access | Times Cited: 106
Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent
Syed Faizan Mehdi, Suma Pusapati, Muhammad Saad Anwar, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 93
New Frontiers in Obesity Treatment: GLP-1 and Nascent Nutrient-Stimulated Hormone-Based Therapeutics
Ania M. Jastreboff, Robert F. Kushner
Annual Review of Medicine (2023) Vol. 74, Iss. 1, pp. 125-139
Open Access | Times Cited: 77
GLP-1a: Going beyond Traditional Use
Lucas Fornari Laurindo, Sandra Maria Barbalho, Élen Landgraf Guiguer, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 2, pp. 739-739
Open Access | Times Cited: 70
Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference for Patients With Obesity or Overweight: A Systematic Review, Meta-analysis, and Meta-regression of 47 Randomized Controlled Trials
Hon Jen Wong, Bee C. Sim, Yao Hao Teo, et al.
Diabetes Care (2025) Vol. 48, Iss. 2, pp. 292-300
Closed Access | Times Cited: 2
The Antiobesity Effect and Safety of GLP-1 Receptor Agonist in Overweight/Obese Patients Without Diabetes: A Systematic Review and Meta-Analysis
Xiaonan Guo, Zhibo Zhou, Xiaorui Lyu, et al.
Hormone and Metabolic Research (2022) Vol. 54, Iss. 07, pp. 458-471
Open Access | Times Cited: 38
An updated pharmacological insight of resveratrol in the treatment of diabetic nephropathy
Ke‐Xue Li, Miao‐Jin Ji, Hai‐Jian Sun
Gene (2021) Vol. 780, pp. 145532-145532
Closed Access | Times Cited: 48
The Emerging Role of Dual GLP-1 and GIP Receptor Agonists in Glycemic Management and Cardiovascular Risk Reduction
Ali A. Rizvi, Manfredi Rizzo
Diabetes Metabolic Syndrome and Obesity (2022) Vol. Volume 15, pp. 1023-1030
Open Access | Times Cited: 36
KDOQI US Commentary on the KDIGO 2020 Clinical Practice Guideline for Diabetes Management in CKD
Amy K. Mottl, Radica Z. Alicic, Christos Argyropoulos, et al.
American Journal of Kidney Diseases (2022) Vol. 79, Iss. 4, pp. 457-479
Open Access | Times Cited: 32
The emerging role of glucagon-like peptide 1 in binge eating
Katherine N. Balantekin, Martin J. Kretz, Elizabeth G. Mietlicki‐Baase
Journal of Endocrinology (2024) Vol. 262, Iss. 1
Open Access | Times Cited: 6
Old Paradoxes and New Opportunities for Appetite Control in Obesity
Léa Montégut, Carlos López‐Otín, Chr̀istophe Magnan, et al.
Trends in Endocrinology and Metabolism (2021) Vol. 32, Iss. 5, pp. 264-294
Open Access | Times Cited: 39
Reappraising the role of the vagus nerve in GLP‐1‐mediated regulation of eating
Daniel I. Brierley, Guillaume de Lartigue
British Journal of Pharmacology (2021) Vol. 179, Iss. 4, pp. 584-599
Open Access | Times Cited: 35
Neurocircuitry underlying the actions of glucagon-like peptide 1 and peptide YY3–36 in the suppression of food, drug-seeking, and anxiogenesis
Yasmina Dumiaty, Brett M. Underwood, Jenny Phy-Lim, et al.
Neuropeptides (2024) Vol. 105, pp. 102427-102427
Open Access | Times Cited: 4
Approved and Emerging Hormone-Based Anti-Obesity Medications: A Review Article
Wael R. Sidrak, Sanjay Kalra, Atul Kalhan
Indian Journal of Endocrinology and Metabolism (2024) Vol. 28, Iss. 5, pp. 445-460
Open Access | Times Cited: 4
Glucagon‐like peptide‐1 receptor agonist‐based agents and weight loss composition: Filling the gaps
Robert L. Dubin, Steven B. Heymsfield, Éric Ravussin, et al.
Diabetes Obesity and Metabolism (2024)
Closed Access | Times Cited: 4
Pharmacological Aspects in the Management of Children and Adolescents with Prader–Willi Syndrome
Jennifer Miller, Shivani Berry, Esraa Ismail
Pediatric Drugs (2025)
Closed Access
The Intricate Relationship Between Circadian Rhythms and Gastrointestinal Peptides in Obesity
Filipe M. Ribeiro, Luiz Arnaldo, Lana Passos, et al.
Peptides (2025), pp. 171356-171356
Closed Access
Microbial dipeptidyl peptidases of the S9B family as host-microbe isozymes
Mashael R. Aljumaah, Jeffrey Roach, Yunan Hu, et al.
Science Advances (2025) Vol. 11, Iss. 14
Closed Access
Perspective: Prospects for Nutraceutical Support of Intestinal Barrier Function
Mark F. McCarty, Aaron Lerner
Advances in Nutrition (2020) Vol. 12, Iss. 2, pp. 316-324
Open Access | Times Cited: 35
Glucagon‐like peptide‐1 in diabetes care: Can glycaemic control be achieved without nausea and vomiting?
Tito Borner, Ian C. Tinsley, Robert P. Doyle, et al.
British Journal of Pharmacology (2021) Vol. 179, Iss. 4, pp. 542-556
Open Access | Times Cited: 31
The role of nucleus of the solitary tract glucagon‐like peptide‐1 and prolactin‐releasing peptide neurons in stress: anatomy, physiology and cellular interactions
Marie K. Holt, Linda Rinaman
British Journal of Pharmacology (2021) Vol. 179, Iss. 4, pp. 642-658
Open Access | Times Cited: 29
GLP-1 receptor agonists, polycystic ovary syndrome and reproductive dysfunction: Current research and future horizons
Georgios S. Papaetis, Angelos Kyriacou
Advances in Clinical and Experimental Medicine (2022) Vol. 31, Iss. 11, pp. 1265-1274
Open Access | Times Cited: 20
The catcher in the gut: Tirzepatide, a dual incretin analog for the treatment of type 2 diabetes mellitus and obesity
Ioannis Lempesis, Jun‐Li Liu, Μaria Dalamaga
Metabolism Open (2022) Vol. 16, pp. 100220-100220
Open Access | Times Cited: 20
Page 1 - Next Page

Scroll to top